CLSD - Clearside Biomedical Inc Debt to Book Capitalization Ratio

The success of Clearside Biomedical (CLSD) is based on the precision of microinjections into the suprachoroidal space and the results of macular edema therapy. The share of borrowed funds in the firm's balance sheet capitalization is derived from the GURU.Markets chart, where the current value is 0.00. Cash flow stability relies on licensing payments, while long-term sustainability is ensured by patent protection of technologies and regular royalties from partners.

CLSD (Clearside Corp) Debt to Book Value history from 07/04/2022 to 12/13/2025

Metric breakdowns and analytics for Clearside Biomedical Inc (CLSD)

- price and consensus price forecast:

Stock Price Clearside Biomedical|CLSD - Analyst Consensus Forecast

- market capitalization data:

Market Value Clearside Corp|CLSD - Value Adjusted for Debt and Cash

- book capitalization data:

Net Assets per Single Share Clearside Biomedical|CLSD - Company Net Assets|Market Capitalization to Book Value Ratio clearsidebio.com|CLSD - Company Total Assets

- debt and liquidity data:

Total Debt to Equity Ratio Clearside Biomedical|CLSD - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Clearside|CLSD - Company Cumulative Debt|Debt to Book Value Clearside Corp

Analysis of all company metrics:Clearside Biomedical - CLSD

Core merchandise of Clearside Biomedical Inc

This indicator assesses the proportion of borrowed funds relative to equity to determine the business's financial stability. Investors track the trend of the debt-to-capitalization ratio to evaluate default risks and pressure on operating profit. A declining curve signals a strengthening balance sheet. For Clearside Biomedical (CLSD), this balance is sustained by the community's confidence in management. Successful licensing deals and innovative injections ensure stable capital.

Competitors of Clearside Biomedical